Repligen Corporation (NASDAQ:RGEN) announced today that Dr. Walter C.
Herlihy, President and Chief Executive Officer of Repligen, will host a
conference call and webcast on Thursday, May 3, 2012 at 8:30 a.m. EDT.
The purpose of the call will be to report first quarter of 2012
financial results and to provide a corporate update.
This call will include an open question and answer period. It is being
webcast by Thomson/CCBN and can be accessed via Repligen’s website at www.repligen.com.
If you are unable to access the webcast, you may listen live by calling 800.591.6923
for domestic calls and 617.614.4907 for international calls.
Participants must provide the following passcode: 27004598.
For those who cannot participate in the live conference call, an archive
of the audio webcast will be available shortly after the call on
Repligen’s website www.repligen.com.
About Repligen Corporation
Repligen Corporation is a leading supplier of critical biologic products
used to manufacture biologic drugs. Repligen also applies its expertise
in biologic product development to RG1068 (SecreFlo™), a synthetic
hormone being developed as a novel imaging agent for the diagnosis of a
variety of pancreatic diseases. In addition, the Company has two central
nervous system (CNS) rare disease programs in Phase 1 clinical trials.
Repligen’s corporate headquarters are located at 41 Seyon Street,
Building #1, Suite 100, Waltham, MA 02453. Additional information may be
requested at www.repligen.com.
This press release contains forward-looking statements, which are
made pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Investors are cautioned that
statements in this press release which are not strictly historical
statements, including, without limitation, express or implied
statements regarding future financial performance and position, the Food
and Drug Administration approval of our NDA for RG1068 (SecreFlo™),
plans and objectives for future operations, plans and objectives for
product development, plans and objectives for regulatory approval,
product development, our market share and product sales and other
statements identified by words like “believe,” “expect,” “may,” “will,”
“should,” “seek,” or “could” and similar expressions, constitute
forward-looking statements. Such forward-looking statements are subject
to a number of risks and uncertainties that could cause actual results
to differ materially from those anticipated, including, without
limitation, risks associated with: our ability to develop and
commercialize products and the market acceptance of our products;
reduced demand for our products that adversely impacts our future
revenues, cash flows, results of operations and financial condition; the
ability to obtain, and the timing and receipt of, FDA approval for our
NDA; our ability to obtain other required regulatory approvals; the
success of current and future collaborative or supply relationships; our
ability to compete with larger, better financed bioprocessing,
pharmaceutical and biotechnology companies; the success of our clinical
trials; new approaches to the treatment of our targeted diseases; our
compliance with all FDA and EMEA regulations; our ability to obtain,
maintain and protect intellectual property rights for our products; the
risk of litigation regarding our intellectual property rights; our
limited sales capabilities; our volatile stock price; and other risks
detailed in Repligen’s annual report on Form 10-K on file with the
Securities and Exchange Commission and the other reports that Repligen
periodically files with the Securities and Exchange Commission. Actual
results may differ materially from those Repligen contemplated by these
forward-looking statements. These forward looking statements reflect
management’s current views and Repligen does not undertake to update any
of these forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date hereof except as
required by law.